Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Heron Therapeutics nets $141.3mm via FOPO

Executive Summary

Heron Therapeutics Inc. (focused on developing therapies for cancer or postoperative pain) netted $141.3mm through the follow-on public offering of 8.57mm common shares at $17.50 each. The company will use the proceeds to launch HTX011 (bupivacaine and meloxicam) for postoperative pain, for ongoing commercialization of Cinvanti (aprepitant) and Sustol (granisetron) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, and for ongoing pipeline development.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies